Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

COGTCogent Biosciences, Inc.Signing up patients

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Advanced Systemic Mastocytosis (AdvSM) · SM With an Associated Hematologic Neoplasm (SM-AHN) · Mast Cell Leukemia (MCL) · Aggressive Systemic Mastocytosis (ASM)

10Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Sep 2025, none posted yet

    Counts until it's fixed

    +10
Worry score10

Score over time

Stage
Phase 2
Patients
140 (planned)
Started
Nov 9, 2021
Main results expected
Sep 19, 2025
Fully finished
Jul 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part I: Identify clinically active and tolerable exposures of bezuclastinib in patients with AdvSM

    Measured over: 18 months

  • Part II: - Determine efficacy of bezuclastinib as measured by mIWG Objective Response Rate (ORR) - Confirm the exposure-response relationship of bezuclastinib

    Measured over: 18 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2025-09-19, no fading

Raw record changes

  • none yet

Trial ID NCT04996875 · record last updated 2026-09-15 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04996875) ↗